101 related articles for article (PubMed ID: 10501821)
1. Clinical pharmacokinetics of ciprofloxacin in patients with major burns.
Lesne-Hulin A; Bourget P; Ravat F; Goudin C; Latarjet J
Eur J Clin Pharmacol; 1999 Sep; 55(7):515-9. PubMed ID: 10501821
[TBL] [Abstract][Full Text] [Related]
2. Ciprofloxacin pharmacokinetics in burn patients.
Garrelts JC; Jost G; Kowalsky SF; Krol GJ; Lettieri JT
Antimicrob Agents Chemother; 1996 May; 40(5):1153-6. PubMed ID: 8723457
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and burn eschar penetration of intravenous ciprofloxacin in patients with major thermal injuries.
Varela JE; Cohn SM; Brown M; Ward CG; Namias N; Spalding PB
J Antimicrob Chemother; 2000 Mar; 45(3):337-42. PubMed ID: 10702553
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
Montgomery MJ; Beringer PM; Aminimanizani A; Louie SG; Shapiro BJ; Jelliffe R; Gill MA
Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics of piperacillin-tazobactam combination in patients with major burns and signs of infection.
Bourget P; Lesne-Hulin A; Le Reveillé R; Le Bever H; Carsin H
Antimicrob Agents Chemother; 1996 Jan; 40(1):139-45. PubMed ID: 8787895
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic modeling of risk factors for ciprofloxacin resistance in Pseudomonas aeruginosa.
Hyatt JM; Schentag JJ
Infect Control Hosp Epidemiol; 2000 Jan; 21(1 Suppl):S9-11. PubMed ID: 10654629
[TBL] [Abstract][Full Text] [Related]
7. Evaluating ciprofloxacin dosing for Pseudomonas aeruginosa infection by using clinical outcome-based Monte Carlo simulations.
Zelenitsky S; Ariano R; Harding G; Forrest A
Antimicrob Agents Chemother; 2005 Oct; 49(10):4009-14. PubMed ID: 16189073
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation.
Rubio TT; Miles MV; Lettieri JT; Kuhn RJ; Echols RM; Church DA
Pediatr Infect Dis J; 1997 Jan; 16(1):112-7; discussion 123-6. PubMed ID: 9002120
[TBL] [Abstract][Full Text] [Related]
9. Ciprofloxacin pharmacokinetics in young cystic fibrosis patients after repeated oral doses.
Odoul F; Le Guellec C; Giraut C; de Gialluly C; Marchand S; Paintaud G; Saux MC; Rolland JC; Autret-Leca E
Therapie; 2001; 56(5):519-24. PubMed ID: 11806288
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of oral ciprofloxacin in continuous cycling peritoneal dialysis.
Yeung SM; Walker SE; Tailor SA; Awdishu L; Tobe S; Yassa T
Perit Dial Int; 2004; 24(5):447-53. PubMed ID: 15490984
[TBL] [Abstract][Full Text] [Related]
11. Comparative study of pharmacokinetics/ pharmacodynamics of ciprofloxacin between 400 mg intravenously every 8 h and 400 mg intravenously every 12 h in patients with gram negative bacilli bacteremia.
Saengsuwan P; Jaruratanasirikul S; Jullangkoon M; Aeinlang N
J Med Assoc Thai; 2010 Jul; 93(7):784-8. PubMed ID: 20649056
[TBL] [Abstract][Full Text] [Related]
12. Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration data.
Burgess DS; Hall RG
Clin Ther; 2007 Jul; 29(7):1421-7. PubMed ID: 17825693
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacokinetic evaluation of linezolid in patients with major thermal injuries].
Le Floch R; Arnould JF; Vinsonneau C; Hovsepian L; Stephanazzi J; Bret P; Birraux G; Lovering AM
Pathol Biol (Paris); 2010 Apr; 58(2):e27-31. PubMed ID: 19854590
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of ciprofloxacin in critically ill patients after the first intravenous administration of 400 mg.
Szałek E; Tomczak H; Kamińska A; Grabowski T; Smuszkiewicz P; Matysiak K; Wolc A; Kaczmarek Z; Grześkowiak E
Adv Med Sci; 2012; 57(2):217-23. PubMed ID: 22968336
[TBL] [Abstract][Full Text] [Related]
15. Ciprofloxacin in polyethylene glycol-coated liposomes: efficacy in rat models of acute or chronic Pseudomonas aeruginosa infection.
Bakker-Woudenberg IA; ten Kate MT; Guo L; Working P; Mouton JW
Antimicrob Agents Chemother; 2002 Aug; 46(8):2575-81. PubMed ID: 12121935
[TBL] [Abstract][Full Text] [Related]
16. [The pharmacodynamics and pharmacokinetics of fluoroquinolones in the evaluation of antibacterial therapy regimens].
Smirnova LB; Sokolova VI
Antibiot Khimioter; 2000; 45(7):14-6. PubMed ID: 10987102
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic-pharmacodynamic analysis of ciprofloxacin in elderly Chinese patients with lower respiratory tract infections caused by Gram-negative bacteria.
Gai XY; Bo SN; Shen N; Zhou QT; Yin AY; Lu W
Chin Med J (Engl); 2019 Mar; 132(6):638-646. PubMed ID: 30855292
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of ciprofloxacin as a tool to optimise dosage schedules in community patients.
Sánchez Navarro MD; Coloma Milano C; Zarzuelo Castañeda A; Sayalero Marinero ML; Sánchez-Navarro A
Clin Pharmacokinet; 2002; 41(14):1213-20. PubMed ID: 12405867
[TBL] [Abstract][Full Text] [Related]
19. Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients.
Pedersen SS; Jensen T; Hvidberg EF
J Antimicrob Chemother; 1987 Oct; 20(4):575-83. PubMed ID: 3479419
[TBL] [Abstract][Full Text] [Related]
20. The ciprofloxacin target AUC : MIC ratio is not reached in hospitalized patients with the recommended dosing regimens.
Haeseker M; Stolk L; Nieman F; Hoebe C; Neef C; Bruggeman C; Verbon A
Br J Clin Pharmacol; 2013 Jan; 75(1):180-5. PubMed ID: 22616681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
